vs
Side-by-side financial comparison of Arrive AI Inc. (ARAI) and CytoMed Therapeutics Ltd (GDTC). Click either name above to swap in a different company.
CytoMed Therapeutics Ltd is the larger business by last-quarter revenue ($115.4K vs $90.7K, roughly 1.3× Arrive AI Inc.).
Arrive AI Inc. develops and delivers AI-powered logistics and supply chain optimization solutions. Its core offerings include intelligent route planning, automated load matching, and operational efficiency tools targeted at e-commerce merchants, freight forwarders, and small-to-medium logistics operators across the North American market, helping cut operational costs and shorten delivery cycles.
CytoMed Therapeutics Ltd is a clinical-stage biopharmaceutical company focused on developing innovative allogeneic chimeric antigen receptor (CAR-T) cell therapies for treating hematological malignancies and solid tumors. It primarily serves global oncology patient populations and advances candidates targeting unmet medical needs in the immuno-oncology segment.
ARAI vs GDTC — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $90.7K | $115.4K |
| Net Profit | $-3.7M | — |
| Gross Margin | — | — |
| Operating Margin | -4066.2% | — |
| Net Margin | -4066.2% | — |
| Revenue YoY | — | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $-0.12 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.5M | — |
| Total Assets | $8.5M | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $4.5M | — |
| Q2 25 | $8.5M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.3M | $-855.3K |
| Free Cash FlowOCF − Capex | — | $-855.4K |
| FCF MarginFCF / Revenue | — | -741.5% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $-3.3M | $-855.3K |
| Q2 25 | — | $-855.4K |
| Q2 25 | — | -741.5% |
| Q2 25 | — | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
